BACKGROUND Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in immunocompromised patients. Based on the pathogen identification status, either empirical (without diagnosis) or targeted (with diagnosis) antifungal therapy is administered to symptomatic patients(e.g. with fever). Several antifungal agents are available and their cost-effectiveness is often evaluated using decision analytic models (DAMs).  OBJECTIVES The objective was to review all published DAMs used in economic evaluations of empirical/targeted antifungal treatments for IFIs. This approach is novel as previous reviews were either pathogen or agent-specific.    METHODS A review was conducted in MEDLINE/EMBASE to identify all economic evaluations that included DAMs published until 1-1-2014. Previous reviews were checked for additional studies. Non-English and studies of prophylactic treatment were excluded. Data extracted included: population, indication, comparators, model structure, time horizon, outcomes, events, year, country, and sponsorship.  RESULTS Overall, 24 published economic evaluations including a DAM were identified. 54% (n=13) were for targeted treatments and the remaining (n=11) for empirical treatments. 62% of the DAMs on targeted treatments (n=8) focused on invasive pulmonary aspergillosis and the remaining 38% (n=5) on invasive candiasis/candidemia. The majority (73%,n=8) of DAMs evaluating empirical treatments focused on patients with persistent fever/febrile neutropenia. Lipid formulation amphotericin-B was a comparator in 46% (n=11) of the studies, followed by caspofungin in 42% (n=10) and voriconazole in 42% (n=10). 92% of the DAMs (n=22) included only a decision tree, whereas the remaining 8% (n=2) embedded a life-time Markov model.  The majority (54%,n=13) had a hospital perspective and time horizon of less than 12 weeks (54%,n=14). Only one study utilized real-world data.           CONCLUSIONS There are major differences in the modeling approach, time horizon, comparator(s), treatment sequences and outcomes of published economic evaluations in IFI. A list of minimal, consensus-based methodological and structural requirements for DAMs on antifungal treatments of IFIs, elicited from key experts is needed.